The department, in consultation with the Center for Medical Cannabis Research created in Section 53H-4-206, shall: (1) develop evidence-based guidance for treatment with medical cannabis based on the latest medical research that shall include: (a) for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis; (b) risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and (c) potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration; (2) educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding: (a) the evidence-based guidance for treatment with medical cannabis described in Subsection (1) (a); (b) relevant warnings and safety information related to medical cannabis use; and (c) other topics related to medical cannabis use as determined by the department; and (3) develop patient product information inserts for medical cannabis products: (a) in consultation with the cannabis processing facility that created the product; and (b) that do not contain proprietary information about the product.
‹ Prev All Utah sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.